Cadwalader Represents The Medicines Company in its Private Offering of $402,500,000 Convertible Senior Notes Due 2023

Jun 16, 2016


Kimberly Brooks
New York
+1 212 504 5652

Cadwalader represented The Medicines Company, a provider of solutions in serious infectious disease care, acute cardiovascular care and surgery and perioperative care, in its private offering of $402,500,000 convertible Senior Notes due 2023.

The aggregate principal amount of notes sold reflects the exercise in full by the initial purchasers of the Notes of their option to purchase up to an additional $52.5 million in aggregate principal amount of Notes.  The Medicines Company estimates that the net proceeds from the offering will be approximately $390.8 million.  The Notes will bear cash interest at a rate of 2.75% per year, payable semi-annually on January 15 and July 15 of each year, beginning on January 15, 2017. The Notes will mature on July 15, 2023.  The Medicines Company intends to use the proceeds of the offering to repurchase certain of its existing convertible Senior Notes in privately negotiated transactions. 

Cadwalader also advised The Medicines Company on related capped call transactions entered into in connection with the convertible Senior Notes offering. 

The New York based Cadwalader team was led by corporate partner Gregory Patti, special counsel Adam Summers, senior attorney Daniel Zimmerman, and, associates Alexandra Cotter and Saadia Ghazi and financial services partner Ray Shirazi and associate Nick Allen.



June 27: SFIG Legal Counsel Forum 2018

Partners Scott Cammarn and Neil Weidner will be speaking at this event in New York City.

Cadwalader's research and intelligence platform provides analysis on changes in U.S. financial regulation. Subscribers receive a daily newsletter interpreting new laws, rules and enforcement actions that impact financial institutions.